Artificial intelligence: a new era in neurology
The integration of artificial intelligence (AI) into the field of neurology has opened the door to unprecedented advancements. From facilitating…
Date: 9th August 2023
The wearables revolution in neurology
Neurologists and researchers are increasingly harnessing the power of wearables to gather real-time, high-quality data about patients’ neurological conditions. From…
Date: 2nd August 2023
Artificial intelligence: a new era in neurology
The integration of artificial intelligence (AI) into the field of neurology has opened the door to unprecedented advancements. From facilitating…
Date: 9th August 2023
The wearables revolution in neurology
Neurologists and researchers are increasingly harnessing the power of wearables to gather real-time, high-quality data about patients’ neurological conditions. From…
Date: 2nd August 2023
α-syn in Parkinson’s disease: cause, biomarker, and treatment target
The causative nature of alpha-synuclein (α-syn) accumulation in Parkinson’s disease pathophysiology has been a subject of debate among researchers, ever…
Date: 25th July 2023
Biomarkers for disease progression and treatment response in MS
Biomarker development and discovery have been an important point in multiple sclerosis (MS) research for many years. Neurofilament light (NfL)…
Date: 29th March 2023
Debating bridging thrombolysis at ISC 2023
Whether the addition of intravenous thrombolysis (IVT) adds benefit beyond what can be achieved with mechanical thrombectomy (MT) alone is…
Date: 10th March 2023
Current and future therapeutic approaches in narcolepsy
Narcolepsy is a chronic neurological disorder of rapid onset eye movement (REM) sleep, affecting the sleep-wake cycle in the brain….
Date: 14th February 2023
Emerging treatment approaches for Parkinson’s disease
Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease, and thus far, only efficacious symptomatic treatments have been developed,…
Date: 3rd February 2023
Research challenges and treatment updates in pediatric migraine
Headaches in children and adolescents have high incidence and prevalence rates, significantly impacting the quality of life and ability to…
Date: 27th January 2023
Seizures can promote more seizures through maladaptive myelination, new findings suggest
Myelin – the insulating layer surrounding neuronal axons – is essential for neuronal function. Once thought to be quite unchanged…
Date: 12th January 2023
The emergence of psychedelic-assisted therapies
Emerging research into the use of psychedelic-assisted therapies to treat a broad spectrum of neurological disorders has sparked great interest…
Date: 3rd January 2023
Pregnancy management in MS and NMOSD
Multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD) are chronic conditions of the central nervous system, predominantly affecting women…
Date: 25th November 2022
Debating intravenous and intra-arterial thrombolysis use in ischemic stroke
Since the landmark clinical trials in 2015, mechanical thrombectomy (MT) has become the gold standard management approach for acute ischemic…
Date: 17th November 2022
MS genetics and environment: new findings
With its prevalence growing globally, multiple sclerosis (MS) is the most common disabling neurologic disease to affect young adults, especially…
Date: 31st October 2022
Key trials in Huntington’s disease: SAGE-718, pridopidine, PTC518, & ANX005
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder, caused by a CAG expansion in the huntingtin (HTT) gene. The…
Date: 19th October 2022
New horizons in hyperkinetic movement disorders
Hyperkinetic movement disorders (HMDs) are characterized by the presence of excessive, abnormal, and involuntary movements and can be isolated or…
Date: 13th October 2022
Update on cenobamate: long-term and subgroup analyses
Cenobamate is an investigational antiepileptic drug with a unique dual mechanism of action: it acts via the reduction of persistent…
Date: 7th October 2022
Novel targets for therapeutic intervention in movement disorders
The development of disease-modifying therapies and the identification of novel actionable targets are at the forefront of research in movement…
Date: 30th September 2022
Improving ALS management: diagnosis and treatment
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with highly variable clinical features and prognosis, making the diagnosis challenging. And…
Date: 9th September 2022
Broadening the use of thrombectomy in stroke management
For acute ischemic stroke with large vessel occlusion, endovascular thrombectomy (EVT) has emerged as the gold standard of care, yet…
Date: 2nd September 2022
Complement inhibitors and FcRn antagonists for myasthenia gravis
Despite existing symptomatic, immunomodulatory, and immunosuppressive therapies, significant unmet needs in myasthenia gravis (MG) treatment remain. Advances in drug development…
Date: 19th August 2022
Novel imaging biomarkers in MS diagnosis and prognostication
Magnetic resonance imaging (MRI) has emerged as a powerful, noninvasive tool for diagnosis, prognostication, and treatment monitoring in multiple sclerosis…
Date: 18th August 2022
Latest guidance on pregnancy and breastfeeding in epilepsy
Women with epilepsy who are pregnant or planning to be pregnant need additional guidance and care due to the complications…
Date: 28th July 2022
Managing migraine: gepants for acute and preventive treatment
Migraine is a debilitating disease with high clinical and social impacts. The calcitonin-gene-related peptide (CGRP) pathway has shown its importance…
Date: 20th July 2022
Latest developments in the treatment of motor fluctuations in Parkinson’s disease
Parkinson’s disease (PD) is the second most common neurodegenerative disorder in the world. This high prevalence of PD has put…
Date: 8th July 2022
Accelerating time to treatment: new approaches to pre-hospital and in-hospital stroke care
Stroke is a highly time-sensitive clinical event and as such, optimizing workflow is of critical importance, even before a patient…
Date: 1st June 2022
Updates in isolated RBD
Isolated RBD (iRBD) has been established as REM sleep behavior disorder without an associated neurodegenerative condition. However, RBD is commonly…
Date: 11th May 2022
Insight into the pathogenesis of pediatric-onset MOGAD
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an inflammatory disorder mainly affecting the optic nerve, spinal cord, and brain. This…
Date: 11th May 2022
Optimizing clinical trial design for improved outcomes in multiple sclerosis
Measuring the efficacy of treatments for multiple sclerosis (MS) is challenging, due to the heterogeneity of disease presentation and the…
Date: 19th April 2022
Clinical trials in neuromuscular disorders: ALS, MG & SMA
Over the past few years, a number of novel treatments for neuromuscular disorders were approved and are now available to…
Date: 21st February 2022
Subtyping in Parkinson’s disease
It is well recognized that Parkinson’s disease (PD) can present with a broad spectrum of motor and non-motor symptoms, and…
Date: 2nd February 2022
Advances in stroke rehabilitation and recovery
Stroke is a leading cause of disability worldwide. Despite considerable improvements in acute stroke treatment, most patients are left with…
Date: 2nd February 2022
